220 related articles for article (PubMed ID: 23589929)
1. Beta amyloid imaging with positron emission tomography (PET) for evaluation of suspected Alzheimer's disease or other causes of cognitive decline.
Technol Eval Cent Assess Program Exec Summ; 2013 Feb; 27(5):1-4. PubMed ID: 23589929
[No Abstract] [Full Text] [Related]
2. Brain amyloid imaging--FDA approval of florbetapir F18 injection.
Yang L; Rieves D; Ganley C
N Engl J Med; 2012 Sep; 367(10):885-7. PubMed ID: 22931256
[No Abstract] [Full Text] [Related]
3. Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist.
Klunk WE
Arch Neurol; 2008 Oct; 65(10):1281-3. PubMed ID: 18852340
[No Abstract] [Full Text] [Related]
4. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
Cortes-Blanco A; Prieto-Yerro C; Martinez-Lazaro R; Zamora J; Jiménez-Huete A; Haberkamp M; Pohly J; Enzmann H; Zinserling J; Strassmann V; Broich K
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S395-9. PubMed ID: 24418060
[TBL] [Abstract][Full Text] [Related]
5. [Amyloid-plaque imaging of the brain using PET].
Ossenkoppele R; Tolboom N; Pijnenburg YA; Lammertsma AA; Scheltens P; van Berckel BN
Ned Tijdschr Geneeskd; 2011; 155():A2981. PubMed ID: 21586182
[TBL] [Abstract][Full Text] [Related]
6. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
[TBL] [Abstract][Full Text] [Related]
7. An imaging agent for amyloid.
Med Lett Drugs Ther; 2012 Jul; 54(1394):54-5. PubMed ID: 22777304
[No Abstract] [Full Text] [Related]
8. Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease.
Wang Y; Klunk WE; Debnath ML; Huang GF; Holt DP; Shao L; Mathis CA
J Mol Neurosci; 2004; 24(1):55-62. PubMed ID: 15314250
[TBL] [Abstract][Full Text] [Related]
9. Florbetapir F 18 for brain imaging of β-amyloid plaques.
Romano M; Buratti E
Drugs Today (Barc); 2013 Mar; 49(3):181-93. PubMed ID: 23527322
[TBL] [Abstract][Full Text] [Related]
10. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
Villemagne VL; Rowe CC
J Alzheimers Dis; 2013; 33 Suppl 1():S349-59. PubMed ID: 22710919
[TBL] [Abstract][Full Text] [Related]
11. Current status of PET-imaging probes of β-amyloid plaques.
Koo J; Byun Y
Arch Pharm Res; 2013 Oct; 36(10):1178-84. PubMed ID: 23812777
[TBL] [Abstract][Full Text] [Related]
12. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
[TBL] [Abstract][Full Text] [Related]
13. PET of brain amyloid and tau in mild cognitive impairment.
Small GW; Kepe V; Ercoli LM; Siddarth P; Bookheimer SY; Miller KJ; Lavretsky H; Burggren AC; Cole GM; Vinters HV; Thompson PM; Huang SC; Satyamurthy N; Phelps ME; Barrio JR
N Engl J Med; 2006 Dec; 355(25):2652-63. PubMed ID: 17182990
[TBL] [Abstract][Full Text] [Related]
14. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease.
Chételat G; Villemagne VL; Bourgeat P; Pike KE; Jones G; Ames D; Ellis KA; Szoeke C; Martins RN; O'Keefe GJ; Salvado O; Masters CL; Rowe CC;
Ann Neurol; 2010 Mar; 67(3):317-24. PubMed ID: 20373343
[TBL] [Abstract][Full Text] [Related]
15. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.
Wolk DA; Zhang Z; Boudhar S; Clark CM; Pontecorvo MJ; Arnold SE
J Neurol Neurosurg Psychiatry; 2012 Sep; 83(9):923-6. PubMed ID: 22791901
[TBL] [Abstract][Full Text] [Related]
16. Florbetapir-PET imaging and postmortem beta-amyloid pathology.
Carome M; Wolfe S
JAMA; 2011 May; 305(18):1857; author reply 1857-8. PubMed ID: 21558513
[No Abstract] [Full Text] [Related]
17. Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis.
de Lartigue J
Drugs Today (Barc); 2014 Mar; 50(3):219-29. PubMed ID: 24696867
[TBL] [Abstract][Full Text] [Related]
18. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
19. Validation of an (18)F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques.
Wey SP; Weng CC; Lin KJ; Yao CH; Yen TC; Kung HF; Skovronsky D; Kung MP
Nucl Med Biol; 2009 May; 36(4):411-7. PubMed ID: 19423009
[TBL] [Abstract][Full Text] [Related]
20. Technology Insight: imaging amyloid plaques in the living brain with positron emission tomography and MRI.
Huddleston DE; Small SA
Nat Clin Pract Neurol; 2005 Dec; 1(2):96-105. PubMed ID: 16932505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]